Non-Small Cell Lung Cancer (Nsclc)-China Drug Forecast and Market Analysis To 2025: Ken Research REQUEST FOR SAMPLE REPORT Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine. In 2015, the NSCLC market in China was an estimated $445M. This growth is fueled by the use of immunotherapies across histologies and lines of therapy in NSCLC, as well as increased access to drugs. Currently, PD-1 inhibitors have not yet launched in China, and thus, there is significant untapped potential for this class of drugs, both in the first- and second-line settings in the Chinese market. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in China from 2015-2025. Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market. Reasons To Buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for NSCLC. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2015-2025 in China. Source: https://www.kenresearch.com/healthcare/pharmaceuticals/non-small-cell-lung-cancer-nsclc-china/80267-91.html Tags: China Non, Small Cell Lung Cancer CAGR China Non, Small Cell Lung Cancer Companies Revenue China Non, Small Cell Lung Cancer Company Profiles, Small Cell Lung Cancer Competition Analysis China Non, Small Cell Lung Cancer Competitive Landscape China Non, Small Cell Lung Cancer Customer preference China Non, Small Cell Lung Cancer Forecast China Non, Small Cell Lung Cancer Future Analysis China Non, Small Cell Lung Cancer Future Projections China Non, Small Cell Lung Cancer Import Export Scenario China Non, Small Cell Lung Cancer Industry Developments China Non, Small Cell Lung Cancer Industry Research Report China Non, Small Cell Lung Cancer Industry Size China Non, Small Cell Lung Cancer Insight China Non, Small Cell Lung Cancer Outlook China Drug Forecast and Market Analysis China Non, Small Cell Lung Cancer Research Report China Non, Small Cell Lung Cancer Sales Growth China Non, Small Cell Lung Cancer Sector Growth China Non, Small Cell Lung Cancer Segmentation China Non, Small Cell Lung Cancer Share China Non, Small Cell Lung Cancer Size China Non, Small Cell Lung Cancer Trends China Non